Key result
Tiagabine pilot study for multiple sclerosis spasms reports no efficacy results.
Why the study?
Painful tonic spasms affect approximately 10% of multiple sclerosis patients and are usually treated with GABAergic drugs, but some patients are nonresponsive or intolerant to established treatments.
Does tiagabine improve painful tonic spasms in multiple sclerosis patients who are non-responsive or intolerant to established treatments?
Population
7 multiple sclerosis patients with painful tonic spasms nonresponsive or intolerant to established drug treatment
Comparison
Tiagabine treatment with dose escalation up to 30 mg/day
Design
Open-label pilot study
Follow-up
3 months
Authors
Loading...
Protocol for tiagabine in refractory MS spasms yields no efficacy data; leaves open whether benefit exists pending completed trials.
Does tiagabine improve painful tonic spasms in multiple sclerosis patients who are non-responsive or intolerant to established treatments?
This pilot study outlines a protocol to evaluate tiagabine for painful tonic spasms in multiple sclerosis, though results are not reported in the provided abstract.
Phillipa J. Lamont (2004) studied Multiple sclerosis with painful tonic spasms (n=7). Tiagabine was evaluated on Subjective level of painful tonic spasms and spasticity level.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: